On October 12, 2026 Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, reported that Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, member of Ernexa’s Scientific Advisory Board, and developer of the technology underlying Ernexa’s platform; and Dr. Robert Pierce, Chief Scientific Officer, will participate in the Virtual Investor Closing Bell Series on Thursday, October 15, 2026, at 4:00 PM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of the segment, Mr. Luther, Dr. Rohde and Dr. Pierce will provide a corporate overview and business outlook, highlighting the science underlying Ernexa’s cell therapy platform and the advancement of lead candidate ERNA-101 toward clinical development. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.

A webcast replay will become available two hours following the live presentation and will be accessible for 90 days.

(Press release, Ernexa Therapeutics, OCT 12, 2026, View Source [SID1234673344])